192 related articles for article (PubMed ID: 38100350)
1. Heterogeneity and transcriptional drivers of triple-negative breast cancer.
Jovanović B; Temko D; Stevens LE; Seehawer M; Fassl A; Murphy K; Anand J; Garza K; Gulvady A; Qiu X; Harper NW; Daniels VW; Xiao-Yun H; Ge JY; Alečković M; Pyrdol J; Hinohara K; Egri SB; Papanastasiou M; Vadhi R; Font-Tello A; Witwicki R; Peluffo G; Trinh A; Shu S; Diciaccio B; Ekram MB; Subedee A; Herbert ZT; Wucherpfennig KW; Letai AG; Jaffe JD; Sicinski P; Brown M; Dillon D; Long HW; Michor F; Polyak K
Cell Rep; 2023 Dec; 42(12):113564. PubMed ID: 38100350
[TBL] [Abstract][Full Text] [Related]
2. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
[TBL] [Abstract][Full Text] [Related]
3. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
4. Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer.
Bansal N; Petrie K; Christova R; Chung CY; Leibovitch BA; Howell L; Gil V; Sbirkov Y; Lee E; Wexler J; Ariztia EV; Sharma R; Zhu J; Bernstein E; Zhou MM; Zelent A; Farias E; Waxman S
Oncotarget; 2015 Oct; 6(33):34087-105. PubMed ID: 26460951
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
6. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
7. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
[TBL] [Abstract][Full Text] [Related]
8. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
9. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y
Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356
[TBL] [Abstract][Full Text] [Related]
10. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.
Huang H; Hu J; Maryam A; Huang Q; Zhang Y; Ramakrishnan S; Li J; Ma H; Ma VWS; Cheuk W; So GYK; Wang W; Cho WCS; Zhang L; Chan KM; Wang X; Chin YR
Nat Commun; 2021 Apr; 12(1):2242. PubMed ID: 33854062
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing.
Radovich M; Clare SE; Atale R; Pardo I; Hancock BA; Solzak JP; Kassem N; Mathieson T; Storniolo AM; Rufenbarger C; Lillemoe HA; Blosser RJ; Choi MR; Sauder CA; Doxey D; Henry JE; Hilligoss EE; Sakarya O; Hyland FC; Hickenbotham M; Zhu J; Glasscock J; Badve S; Ivan M; Liu Y; Sledge GW; Schneider BP
Breast Cancer Res Treat; 2014 Jan; 143(1):57-68. PubMed ID: 24292813
[TBL] [Abstract][Full Text] [Related]
12. miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.
Lv ZD; Kong B; Liu XP; Jin LY; Dong Q; Li FN; Wang HB
J Cell Mol Med; 2016 May; 20(5):864-73. PubMed ID: 26820102
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
[No Abstract] [Full Text] [Related]
14. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
16. Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype.
Angius A; Pira G; Cossu-Rocca P; Sotgiu G; Saderi L; Muroni MR; Virdis P; Piras D; Vincenzo R; Carru C; Coradduzza D; Uras MG; Cottu P; Fancellu A; Orrù S; Uva P; De Miglio MR
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3951-3963. PubMed ID: 36030436
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
19. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Franco HL; Nagari A; Malladi VS; Li W; Xi Y; Richardson D; Allton KL; Tanaka K; Li J; Murakami S; Keyomarsi K; Bedford MT; Shi X; Li W; Barton MC; Dent SYR; Kraus WL
Genome Res; 2018 Feb; 28(2):159-170. PubMed ID: 29273624
[TBL] [Abstract][Full Text] [Related]
20. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]